Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.56 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.53 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.53 |
| ▸ | MC4R | P32245 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 3/20 | 0.51 |
| ▸ | MEN1 | O00255 | 3/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | DRD2 | P14416 | 1/20 | 0.49 |
| ▸ | DRD4 | P21917 | 1/20 | 0.49 |
| ▸ | DRD3 | P35462 | 1/20 | 0.49 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20571573 | 0.83 | CYP3A4 (0.59) | CYP3A4HSD17B10SIGMAR1CYP2C9CYP2C19 | |
| SCHEMBL11727640 | 0.81 | CYP2D6 (0.52) | CYP3A4CYP2D6POLBMEN1KMT2A | |
| SCHEMBL2817086 | 0.77 | CYP2D6 (0.67) | CYP3A4SIGMAR1CYP2C9CYP2C19CYP2D6 | |
| SCHEMBL4716779 | 0.77 | MAPT (0.41) | CYP2D6POLBMEN1KMT2AALDH1A1 | |
| SCHEMBL12013906 | 0.77 | SIGMAR1 (0.65) | CYP3A4HSD17B10SIGMAR1CYP2C9CYP2C19 | |
| SCHEMBL11277475 | 0.76 | CYP3A4 (0.51) | CYP3A4HSD17B10SIGMAR1CYP2C9CYP2C19 | |
| SCHEMBL8809190 | 0.76 | CYP3A4 (0.66) | CYP3A4SIGMAR1CYP2C9CYP2C19CYP2D6 | |
| SCHEMBL6530831 | 0.76 | CYP2D6 (0.66) | CYP3A4SIGMAR1CYP2C9CYP2C19CYP2D6 | |
| SCHEMBL22050089 | 0.75 | OPRL1 (0.55) | CYP3A4HSD17B10SIGMAR1CYP2C9CYP2C19 | |
| Ammonia Solution, Strong SCHEMBL14735243 | 0.75 | SIGMAR1 (0.63) | CYP3A4HSD17B10SIGMAR1CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9670487-B2 | Cationic lipids for oligonucleotide delivery | SIRNA THERAPEUTICS, INC. (US) | 2017-06-06 | — | — | US | disclosed |
| US-20130053572-A1 | Novel Cationic Lipids for Oligonucleotide Delivery | BANK OF AMERICA, N.A. | 2013-02-28 | — | — | US | disclosed |
| WO-2011090965-A1 | NOVEL CATIONIC LIPIDS FOR OLIGONUCLEOTIDE DELIVERY | MERCK SHARP & DOHME CORP. (US) | 2011-07-28 | — | — | WO | disclosed |
| US-7442701-B2 | Amino-heterocycles as VR-1 antagonists for treating pain | MERCK SHARP & DOHME LTD. (GB) | 2008-10-28 | — | — | US | disclosed |
| EP-1562934-B1 | AMINO-HETEROCYCLES AS VR-1 ANTAGONISTS FOR TREATING PAIN | MERCK SHARP & DOHME (GB) | 2008-03-26 | — | — | EP | disclosed |
| US-20060040947-A1 | Amino-heterocycles as vr-1 antagonists for treating pain | MERCK SHARP & DOHME LTD. (GB) | 2006-02-23 | — | — | US | disclosed |
| EP-1562934-A1 | AMINO-HETEROCYCLES AS VR-1 ANTAGONISTS FOR TREATING PAIN | MERCK SHARP & DOHME LTD. (GB) | 2005-08-17 | — | — | EP | disclosed |
| WO-2004046133-A1 | AMINO-HETEROCYCLES AS VR-1 ANTAGONISTS FOR TREATING PAIN | MERCK SHARP & DOHME LIMITED (GB) | 2004-06-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130053572-A1 | Novel Cationic Lipids for Oligonucleotide Delivery | NPC1L1, CETP, LIPA | CYP3A4 1435/4885HSD17B10 415/4885SIGMAR1 384/4885 |
| US-20060040947-A1 | Amino-heterocycles as vr-1 antagonists for treating pain | OPRL1, CNR1, GPR6 | CYP3A4 977/4885HSD17B10 1178/4885SIGMAR1 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.